Drug copays are sometimes higher than out-of-pocket costs

As the debate around rising drug prices heightens, pharmacy benefit managers (PBMs) are taking on more scrutiny over copays that are sometimes higher than buying the drug out of pocket.

According to a recent study, insurance copays are higher than the cost of the drug about 25 percent of the time, PBS reported. Many patients don’t know that they can save money by buying a prescription drug without their insurance. And the high prices under copays for some drugs thrusts PBMs, which negotiate prices with drug companies, back into the spotlight.

“You have insurance because your belief is, you’re paying premiums, so when you need care, a large fraction of that cost is going to be borne by your insurance company,” Geoffrey Joyce, a USC economist and co-author of the study, told PBS. “The whole notion that you are paying more for the drug with insurance is just mind boggling, to think that they’re doing this and getting away with it.”

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.